
Ugur Sahin
Net worth: 3 845 M $ as of 2026-05-30

Net worth: 3 845 M $ as of 2026-05-30
Founder of BioNTech SE, Ganymed Pharmaceuticals AG, Ci3 Management UG and TRON - Translationale Onkologie an der Universitätsmedizin der, Ugur Sahin currently is Chief Executive Officer for BioNTech SE and Managing Director at reBOOST Management GmbH (a subsidiary of BioNTech SE) and Managing Director at Medine GmbH. Dr. Sahin is also Professor at Universitätsmedizin der Johannes Gutenberg-Universität Mainz. He previously occupied the position of Chief Medical Officer for Ganymed Pharmaceuticals AG and Co-Managing Director at TRON - Translationale Onkologie an der Universitätsmedizin der. Dr. Sahin received a doctorate from Universität zu Köln.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BIONTECH SE 16.59% | 2026-03-30 | 40,076,320 ( 16.59% ) | 3 845 M $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| BIONTECH SE | Chief Executive Officer | 2008-06-01 |
reBOOST Management GmbH
reBOOST Management GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Chief Executive Officer | 2018-10-22 |
Medine GmbH
Medine GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Chief Executive Officer | 2011-03-13 |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Medical/Nursing ServicesHealth Services Provides health care facilities and services | Corporate Officer/Principal | 2013-12-31 |
Helmholtz Institute For Translational Oncology | Corporate Officer/Principal | - |
BioNTech Delivery Technologies GmbH
BioNTech Delivery Technologies GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of immunotherapies | Chief Executive Officer | - |
| Companies | Position | End |
|---|---|---|
TRON - Translationale Onkologie an der Universitätsmedizin der
TRON - Translationale Onkologie an der Universitätsmedizin der Miscellaneous Commercial ServicesCommercial Services Operates as biopharmaceutical research organization | Chief Executive Officer | 2018-12-31 |
Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Develops antibodies for the treatment of solid cancers | Founder | 2010-07-29 |
Ci3 Management UG | Founder | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 10 |
|---|---|
Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Develops antibodies for the treatment of solid cancers | Health Technology |
Universität zu Köln
Universität zu Köln Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioNTech SE
BioNTech SE BiotechnologyHealth Technology Develops immunotherapies and mRNA-based vaccines to treat cancer & infectious diseases | Health Technology |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Medical/Nursing ServicesHealth Services Provides health care facilities and services | Health Services |
Ci3 Management UG | |
TRON - Translationale Onkologie an der Universitätsmedizin der
TRON - Translationale Onkologie an der Universitätsmedizin der Miscellaneous Commercial ServicesCommercial Services Operates as biopharmaceutical research organization | Commercial Services |
Medine GmbH
Medine GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Commercial Services |
reBOOST Management GmbH
reBOOST Management GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Commercial Services |
BioNTech Delivery Technologies GmbH
BioNTech Delivery Technologies GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of immunotherapies | Commercial Services |
Helmholtz Institute For Translational Oncology |
Select your edition
All financial news and data tailored to specific country editions